Dr. Rachel Parker -- Pharmaceutical Payment Report

This page provides a comprehensive transparency report for Dr. Rachel Parker, a Pediatrics physician based in Cleveland, OH. All payment data is sourced from the CMS Open Payments (Sunshine Act) database. Dr. Rachel Parker has received $11,682.30 in total pharmaceutical industry payments across 1 transactions from 1 pharmaceutical companies.

Physician Profile

The following profile information is sourced from the National Provider Identifier (NPI) registry and CMS Open Payments records.

Payment Summary

Dr. Rachel Parker has received a total of $11,682.30 in pharmaceutical industry payments across 1 recorded transactions in the CMS Open Payments database. The average payment amount is $11,682.30 per transaction.

Payment Breakdown by Category

The following table shows how Dr. Rachel Parker's pharmaceutical payments break down by payment category. Understanding the mix of payment types provides important context about the nature of the doctor-pharma relationship.

Payment CategoryAmountDescription
Consulting Fees$11,682.30Advisory board participation, clinical consulting, and expert opinion services

The largest payment category for Dr. Rachel Parker is Consulting Fees, accounting for 100% ($11,682.30) of total pharmaceutical payments received. This suggests active involvement in pharmaceutical company advisory and educational programs.

Pharmaceutical Company Relationships

The following pharmaceutical and medical device companies have made payments to Dr. Rachel Parker. Click on any company name to view their full physician payment profile and spending patterns.

CompanyTotal PaidTransactions
Vertex Pharmaceuticals$11,682.301

Dr. Rachel Parker has a financial relationship with Vertex Pharmaceuticals, receiving $11,682.30 in total. Having a single pharmaceutical company relationship means all payments come from one source, which may indicate a focused consulting or research relationship.

AI Transparency Analysis

The following analysis was generated by artificial intelligence based on Dr. Rachel Parker's payment history, specialty peer comparisons, and payment pattern analysis. This analysis is not medical or legal advice.

Rachel Parker has received $11.7K across 1 pharmaceutical payments as a Pediatrics physician in Cleveland, OH. Top paying companies include Vertex Pharmaceuticals ($11.7K). Dr. Parker received a single payment of $11,682 in 2026, indicating a recent engagement. The entire payment came from Vertex Pharmaceuticals, suggesting a focused relationship with this company. This payment was categorized as consulting, highlighting the nature of the service provided.

Patient Guidance: Questions to Ask Your Doctor

If Dr. Rachel Parker is your physician, here is practical guidance on how to understand and discuss pharmaceutical industry relationships:

As a patient, understand that while this payment is disclosed, it represents a single instance of engagement. It's always wise to discuss treatment options and potential conflicts of interest directly with your doctor. Always feel free to ask your doctor directly about their pharmaceutical relationships.

Peer Comparison: How Dr. Rachel Parker Compares to Other Pediatrics Physicians

For pediatricians, a single large payment from one company is less common than multiple smaller payments from various pharmaceutical entities.

Recent Payment Records

The following table shows the most recent pharmaceutical industry payments recorded for Dr. Rachel Parker in the CMS Open Payments database. Click on any payment to view the full report.

CompanyAmountTypeDrug/DeviceDateConflict Level
Vertex Pharmaceuticals$11,682.30consultingN/A2026-02-09Not Assessed

Frequently Asked Questions About Dr. Rachel Parker's Pharma Payments

Below are common questions patients ask about physician pharmaceutical payment data.

How much pharma money has Rachel Parker received?

Rachel Parker has received a total of $11.7K across 1 payments from pharmaceutical companies. This data is publicly reported under the CMS Open Payments (Sunshine Act) program.

Is Rachel Parker taking too much pharma money?

Rachel Parker has received $11.7K in pharmaceutical payments. Whether this is "too much" depends on the physician's specialty (Pediatrics), the types of payments, and how they compare to peers. The largest payment category is consulting ($11.7K). Payment does not imply wrongdoing, but patients should be aware and can ask their doctor directly.

What pharma companies pay Rachel Parker?

The top pharmaceutical companies paying Rachel Parker are: Vertex Pharmaceuticals ($11.7K). These payments cover various categories including consulting, meals, speaking fees, and research grants.

What kinds of payments does Rachel Parker receive?

Rachel Parker's payments by type: consulting: $11.7K. Consulting fees suggest active advisory roles with pharmaceutical companies.

Should I switch doctors because of pharma payments?

Pharma payments alone are not typically reason to switch doctors. Many payments are routine (like meals at educational events) and do not indicate compromised care. Focus on: (1) whether your doctor explains treatment options clearly, (2) whether generic alternatives are discussed, (3) the overall pattern of payments, not individual transactions. If you have concerns, ask your doctor directly.

How do Rachel Parker's payments compare to other Pediatrics doctors?

To compare, look at the total amount ($11.7K), number of payments (1), and the types of payments received. Pediatrics physicians may receive different payment amounts depending on subspecialty, geographic location, and academic affiliation. Use CMS Open Payments data to compare across the specialty.

How can I verify Rachel Parker's payment data?

You can verify this data directly through the CMS Open Payments database at openpaymentsdata.cms.gov. Search by physician name or NPI number (1271527553). All data is reported by pharmaceutical companies and verified by CMS. DoctorPharmaData aggregates this public data for easier access.

Do pharma payments affect prescribing quality?

Research published in JAMA Internal Medicine and other peer-reviewed journals shows a statistical association between pharmaceutical payments and prescribing patterns. However, correlation does not equal causation. Many physician-industry interactions are legitimate (research, education, advisory boards). The Sunshine Act was created to promote transparency so patients can make informed decisions.

What stands out about Rachel Parker's pharma payment profile?

The doctor's payment profile is very narrow, with only one payment from one company. Rachel Parker has received $11.7K in total pharma payments.

How does Rachel Parker compare to peers in Pediatrics?

For pediatricians, a single large payment from one company is less common than multiple smaller payments from various pharmaceutical entities.

Are Rachel Parker's pharma relationships typical for Pediatrics?

The high average payment ($11,682) for a single transaction suggests a significant consulting role or project.

What should patients of Rachel Parker know about these payments?

As a patient, understand that while this payment is disclosed, it represents a single instance of engagement. It's always wise to discuss treatment options and potential conflicts of interest directly with your doctor.

What patterns are visible in Rachel Parker's payment history?

The 100% top company concentration indicates a complete reliance on Vertex Pharmaceuticals for disclosed payments.

Understanding This Doctor Payment Report

This transparency report for Dr. Rachel Parker is based on data from the CMS Open Payments database, which is maintained by the Centers for Medicare and Medicaid Services under the Physician Payments Sunshine Act. Here are important things to understand:

About the Physician Payments Sunshine Act

The Physician Payments Sunshine Act, enacted as Section 6002 of the Affordable Care Act in 2010, requires pharmaceutical and medical device companies to report payments and other transfers of value to physicians and teaching hospitals to CMS. This law was designed to increase transparency in the financial relationships between the healthcare industry and medical providers.

Under this law, Dr. Rachel Parker's pharmaceutical payments are publicly disclosed. The types of reportable transactions include consulting fees, compensated speaking or educational activities, honoraria, gifts, entertainment, food and beverages, travel and lodging, education or conference attendance, research grants, charitable contributions, royalties or licenses, current or prospective ownership interests, and direct compensation for services other than consulting.

The Open Payments data for Dr. Rachel Parker and all other physicians can be accessed at the official CMS Open Payments website.

Related Resources

Data from CMS Open Payments (Sunshine Act). Payment does not imply wrongdoing. AI analysis is not medical or legal advice. Consult your healthcare provider about any concerns.